Form 4: Candel Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Paul B Manning, a Director of Candel Therapeutics, Inc., received 2,189 shares of common stock on September 30, 2026.
Summary
- Grant/award: acquired 2,189 Stock Option (Right to Buy) at $8.68 ($18,992) on September 30, 2026; holds 2,189 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Paul B Manning — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Grant/award | Stock Option (Right to Buy) | 2,189 | $9 | $19.0K | 2,189 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Grant/award (2,189 shares) |
Keywords
insider transaction, Form 4, CADL, Candel Therapeutics, Inc., neutral, Paul B Manning
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.